11/26/2022 0 Comments Facebook beta bionics![]() ![]() ![]() The glucagon-only configuration may be helpful in rare, chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI) and insulinoma syndrome. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a dual-hormone bionic pancreas (insulin and glucagon). The iLet is effectively three medical devices in one. 2014, 371:313-25 Lancet Diabetes and Endocrinology. These improvements included significant reductions in blood-glucose levels, in hypoglycemia, and in intersubject and intrasubject glycemic variability (New England Journal of Medicine. In previous home-use studies in adults and children with T1D, these algorithms demonstrated dramatic improvements in glycemic control relative to the standard of care. Immediately thereafter, the iLet begins controlling blood-sugar levels automatically, without requiring the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections. To initialize the iLet, users enter only their body weight. Embedded in the system are clinically tested mathematical dosing algorithms driven by lifelong autonomous learning to automatically calculate and dose insulin and/or glucagon as needed, based on data from a continuous glucose monitor. The iLet consists of a dual-chamber, pocket-sized, wearable medical device that autonomously controls blood-sugar levels in people with diabetes. Published clinical data has clearly surpassed our expectations to the potential of bihormonal infusion therapy and we are excited to be part of this development”, John M. Being the world’s largest manufacturer of infusion sets within diabetes technology, and committed to highest standards in patient safety, product efficacy and patient-centered design, we will do our utmost to support this exciting programme. “We at Unomedical are proud to be selected by Beta Bionics as infusion set partner for the iLet Bionic Pancreas system. Making the world’s most popular infusion sets compatible with the iLet is very exciting for us, and underscores our deep commitment to patient choice.” “We are very impressed with Unomedical’s products and world class manufacturing capabilities, and have great confidence in their steel and flexible-cannula infusion sets, having used them in all of our iLet clinical studies. “Under the Beta Bionics public benefit structure, we are committed to acting in the best interests of the type 1 diabetes community with every decision that we make” said Ed Damiano, co-founder and CEO of Beta Bionics. ConvaTec’s Unomedical subsidiary develops, produces, and supplies a range of disposable infusion sets used in insulin infusion therapy, including their highly popular flexible-cannula sets currently used with insulin pumps today. The Unomedical sets will be deployed in two pivotal trials testing the iLet in its insulin-only and bihormonal (insulin and glucagon) configurations in 2020. The arrangement is non-exclusive, consistent with other Beta Bionics partnerships designed to protect patient choice. The arrangement between Beta Bionics and ConvaTec creates a deep and meaningful partnership between the two companies for the benefit of the diabetes community. a medical technology company leveraging lifelong autonomous learning to develop and commercialize the world’s first fully automated bionic pancreas - and ConvaTec Group Plc (LSE: CTEC) - a leading global medical products and technologies company - today announced that ConvaTec’s Unomedical subsidiary and Beta Bionics have entered into a collaboration and development agreement that will make portions of Unomedical’s world class infusion sets available for use with the iLet Bionic Pancreas System.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |